var data={"title":"Omalizumab: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Omalizumab: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6679?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=omalizumab-drug-information\" class=\"drug drug_general\">see &quot;Omalizumab: Drug information&quot;</a> and <a href=\"topic.htm?path=omalizumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Omalizumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709181\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Anaphylaxis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of omalizumab. Anaphylaxis has occurred as early as after the first dose of omalizumab but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, observe patients closely for an appropriate period of time after omalizumab administration. Health care providers administering omalizumab should be prepared to manage anaphylaxis that can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care if symptoms occur.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203365\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Xolair</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855143\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Xolair</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060686\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Monoclonal Antibody, Anti-Asthmatic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060679\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=omalizumab-drug-information\" class=\"drug drug_general\">see &quot;Omalizumab: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Asthma:</b> Dose and frequency based on body weight and pretreatment total IgE serum concentrations. Dosing should be adjusted during therapy for significant changes in body weight. Dosing should <b>not</b> be adjusted based on total IgE concentrations taken during treatment or if there is an interruption of therapy &lt;1 year in duration as  total IgE concentrations are elevated during treatment and remain elevated for up to 1 year after discontinuation of treatment. If therapy has been interrupted for &ge;1 year, total IgE levels may be reevaluated for dosage determination. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Children &ge;12 years and Adolescents: SubQ: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Pretreatment serum IgE &ge;30 to 100 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">30 to 90 kg: 150 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;90 to 150 kg: 300 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Pretreatment serum IgE &gt;100 to 200 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">30 to 90 kg: 300 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;90 to 150 kg: 225 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Pretreatment serum IgE &gt;200 to 300 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">30 to 60 kg: 300 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;60 to 90 kg: 225 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;90 to 150 kg: 300 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Pretreatment serum IgE &gt;300 to 400 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">30 to 70 kg: 225 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;70 to 90 kg: 300 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;90 kg: Do not administer dose </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Pretreatment serum IgE &gt;400 to 500 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">30 to 70 kg: 300 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;70 to 90 kg: 375 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;90 kg: Do not administer dose </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Pretreatment serum IgE &gt;500 to 600 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">30 to 60 kg: 300 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;60 to 70 kg: 375 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;70 kg: Do not administer dose </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Pretreatment serum IgE &gt;600 to 700 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">30 to 60 kg: 375 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;60 kg: Do not administer dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Children &ge;6 years and Adolescents: SubQ: Dose and frequency based on body weight and pretreatment IgE serum concentrations to provide a minimum dose of 0.016 mg/kg/unit of IgE every 4 weeks has been used in some placebo-controlled trials (Busse 2011; Milgrom 2001). One study used the below algorithm to ensure the minimum dose was achieved (Busse 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pretreatment serum IgE &ge;30 to 100 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 40 kg: 75 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;40 to 90 kg: 150 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;90 to 150 kg: 300 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pretreatment serum IgE &gt;100 to 200 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 40 kg: 150 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;40 to 90 kg: 300 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;90 to 125 kg: 225 mg every 2 weeks  </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;125 to 150 kg: 300 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pretreatment serum IgE &gt;200 to 300 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 30 kg: 150 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;30 to 40 kg: 225 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;40 to 60 kg: 300 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;60 to 90 kg: 225 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;90 to 125 kg: 300 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;125 to 150 kg: 375 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pretreatment serum IgE &gt;300 to 400 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 30 kg: 225 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;30 to 40 kg: 300 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;40 to 70 kg: 225 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;70 to 90 kg: 300 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;90 kg: Do not administer dose </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pretreatment serum IgE &gt;400 to 500 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 25 kg: 225 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;25 to 30 kg: 300 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;30 to 50 kg: 225 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;50 to 70 kg: 300 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;70 to 90 kg: 375 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;90 kg: Do not administer dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pretreatment serum IgE &gt;500 to 600 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 30 kg: 300 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;30 to 40 kg: 225 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;40 to 60 kg: 300 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;60 to 70 kg: 375 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;70 kg: Do not administer dose </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pretreatment serum IgE &gt;600 to 700 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 25 kg: 300 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;25 to 40 kg: 225 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;40 to 50 kg: 300 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;50 to 60 kg: 375 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;60 kg: Do not administer dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pretreatment serum IgE &gt;700 to 900 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 30 kg: 225 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;30 to 40 kg: 300 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;40 to 50 kg: 375 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;50 kg: Do not administer dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pretreatment serum IgE &gt;900 to 1,100 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 25 kg: 225 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;25 to 30 kg: 300 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;30 to 40 kg: 375 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;40 kg: Do not administer dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pretreatment serum IgE &gt;1,100 to 1,200 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 30 kg: 300 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;30 kg: Do not administer dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pretreatment serum IgE &gt;1,200 to 1,300 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 25 kg: 300 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;25 to 30 kg: 375 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;30 kg: Do not administer dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Chronic idiopathic urticaria:</b> Children &ge;12 years and Adolescents: SubQ: 150 or 300 mg every 4 weeks. Dosing is not dependent on serum IgE (free or total) level or body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Asthma:</b> SubQ: Dose and frequency based on body weight and <b>pretreatment</b> total IgE serum levels. Dosing should be adjusted during therapy for significant changes in body weight. Dosing should <b>not</b> be adjusted based on total IgE levels taken during treatment or &lt;1 year following interruption of therapy. If therapy has been interrupted for &ge;1 year, total IgE levels may be reevaluated for dosage determination.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pretreatment serum IgE &ge;30 to 100 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">30 to 90 kg: 150 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;90 to 150 kg: 300 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pretreatment serum IgE &gt;100 to 200 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">30 to 90 kg: 300 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;90 to 150 kg: 225 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pretreatment serum IgE &gt;200 to 300 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">30 to 60 kg: 300 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;60 to 90 kg: 225 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;90 to 150 kg: 300 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pretreatment serum IgE &gt;300 to 400 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">30 to 70 kg: 225 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;70 to 90 kg: 300 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;90 kg: Do not administer dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pretreatment serum IgE &gt;400 to 500 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">30 to 70 kg: 300 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;70 to 90 kg: 375 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;90 kg: Do not administer dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pretreatment serum IgE &gt;500 to 600 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">30 to 60 kg: 300 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;60 to 70 kg: 375 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;70 kg: Do not administer dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pretreatment serum IgE &gt;600 to 700 units/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">30 to 60 kg: 375 mg every 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;60 kg: Do not administer dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic idiopathic urticaria:</b> SubQ: 150 or 300 mg every 4 weeks. Dosing is not dependent on serum IgE (free or total) level or body weight.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203343\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xolair: 150 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203329\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874749\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089829.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlPFrwuTw3qXEGaybSedlTcA==&amp;TOPIC_ID=12905\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089829.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060690\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Doses &gt;150 mg should be divided into more than one injection site (eg, 225 mg or 300 mg administered as two injections, 375 mg administered as three injections). Due to viscosity, injection may take 5 to 10 seconds to administer. Administer only under direct medical supervision and observe patient for a minimum of 2 hours following administration of any dose given.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203360\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to reconstitution, store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); product may be shipped at room temperature. Following reconstitution, protect from direct sunlight. May be stored for up to 8 hours if refrigerated or 4 hours if stored at room temperature &le;30&deg;C (&le;86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060689\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of moderate to severe, persistent asthma in patients who have a positive skin test or in vitro reactivity to a perennial aeroallergen  whose symptoms are not adequately controlled with inhaled corticosteroids (FDA approved in ages &ge;12 years and adults); treatment of chronic idiopathic urticaria in patients who remain symptomatic despite H<sub>1</sub> antihistamine treatment (FDA approved in ages &ge;12 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9525624\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Omalizumab may be confused with obinutuzumab, ofatumumab</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203387\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Myocardial infarction, pulmonary embolism, unstable angina pectoris, venous thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, fatigue, pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatitis, pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (includes bruising, redness, warmth, burning, stinging, itching, hive formation, pain, indurations, mass, and inflammation; most reactions occurred within 1 hour, lasted &lt;8 days, and decreased in frequency with additional dosing)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arm pain, arthralgia, bone fracture, leg pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rare but important or life-threatening: Alopecia, anaphylaxis, antibody development, arthritis, lymphadenopathy, malignant neoplasm, syncope, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic idiopathic urticaria:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety, headache, migraine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Toothache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Fungal infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, limb pain, musculoskeletal pain, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Asthma, cough, nasopharyngitis, oropharyngeal pain, sinus headache, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection</p>\n    <p style=\"text-indent:-6em;margin-left:8em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>All indications:</b> Rare but important or life-threatening: Alopecia, anaphylaxis, antibody development, arthritis, chest tightness, eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss), lymphadenopathy, malignant neoplasm, pulmonary hypertension, syncope, thrombocytopenia, transient ischemic attacks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203348\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Severe hypersensitivity reaction to omalizumab or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203333\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Cerebrovascular events, including transient ischemic attack and ischemic stroke, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Eosinophilia and vasculitis: In rare cases, patients may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss), a condition which is often treated with systemic corticosteroid therapy. Health care providers should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between omalizumab and these underlying conditions has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fever/arthralgia/rash: Reports of a constellation of symptoms including fever, arthritis or arthralgia, rash, and lymphadenopathy have been reported with postmarketing use (symptoms resemble those seen in patients experiencing serum sickness, although circulating immune complexes or a skin biopsy consistent with a Type III hypersensitivity reaction were not seen with these cases). Onset of symptoms generally occurred 1 to 5 days following the first or subsequent doses. Discontinue therapy in any patient reporting this constellation of signs/symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactoid reactions: <b>[US Boxed Warning]: Anaphylaxis, including delayed-onset anaphylaxis, has been reported following administration; anaphylaxis may present as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue. Anaphylaxis has occurred after the first dose and in some cases &gt;1 year after initiation of regular treatment. Due to the risk, patients should be observed closely for an appropriate time period after administration and should receive treatment only under direct medical supervision. Healthcare providers should be prepared to administer appropriate therapy for managing potentially life-threatening anaphylaxis. Patients should be instructed on identifying signs/symptoms of anaphylaxis and to seek immediate care if they arise.</b> In postmarketing reports, anaphylaxis usually occurred with the first or second dose and with a time to onset of &le;60 minutes; however, reactions have been reported with subsequent doses (after 39 doses) and with a time to onset of up to 4 days after administration. A case-control study showed that patients with a history of anaphylaxis to foods, medications, or other causes were at an increased risk of anaphylaxis. Discontinue therapy following any severe reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignant neoplasms: Have been reported rarely with use in short-term studies; impact of long-term use is not known.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parasitic infections: Use with caution and monitor patients at high risk for parasitic (helminth) infections; risk of infection may be increased; appropriate duration of continued monitoring following therapy discontinuation has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Corticosteroid therapy: Gradually taper systemic or inhaled corticosteroid therapy; do not discontinue corticosteroids abruptly following initiation of omalizumab therapy. The combined use of omalizumab and corticosteroids in patients with chronic idiopathic urticaria has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Therapy has not been shown to alleviate acute asthma exacerbations; do not use to treat acute bronchospasm, status asthmaticus, or other allergic conditions. Do not use to treat forms of urticaria other than chronic idiopathic urticaria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dosing/IgE levels: Dosing for asthma is based on body weight and pretreatment total IgE serum levels. IgE levels remain elevated up to 1 year following treatment; therefore, levels taken during treatment or for up to 1 year following treatment cannot and should not be used as a dosage guide. Dosing in chronic idiopathic urticaria is not dependent on serum IgE (free or total) level or body weight.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299788\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221997\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12905&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203350\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. IgG molecules are known to cross the placenta. Information related to the use of omalizumab in pregnancy is available from case reports of women with severe asthma (Kupry&#347;-Lipi&#324;ska 2014) or chronic idiopathic urticaria (some also with asthma) (Cuervo-Pardo 2016; Ghazanfar 2015). In addition, preliminary data from the Xolair Pregnancy Registry (EXPECT) has been published. Based on data collected from 191 women September 2006 through November 2012, the incidence of the adverse events monitored (major congenital malformations, prematurity, low birth weight, small for gestational age) are within the rates of those reported for women with severe asthma (Namazy 2015). The pregnancy registry has closed; however, new cases of exposure may be reported to the manufacturer (Genentech 888-835-2555).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, pre-eclampsia, preterm birth, low-birth-weight infants). Optimal control of asthma prior to and during pregnancy is recommended (GINA 2016; NAEPP 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060685\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline total serum IgE, FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests, anaphylactic/hypersensitivity reactions;  monitor for signs of infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203332\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asthma: Omalizumab is an IgG monoclonal antibody (recombinant DNA derived) which inhibits IgE binding to the high-affinity IgE receptor on mast cells and basophils. By decreasing bound IgE, the activation and release of mediators in the allergic response (early and late phase) is limited. Serum free IgE levels and the number of high-affinity IgE receptors are decreased. Long-term treatment in patients with allergic asthma showed a decrease in asthma exacerbations and corticosteroid usage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Chronic idiopathic urticaria: Omalizumab binds to IgE and lowers free IgE levels. Subsequently, IgE receptors (Fc&epsilon;RI) on cells down-regulate. The mechanism by which these effects of omalizumab result in an improvement of chronic idiopathic urticaria symptoms is unknown. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203347\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Response to therapy: ~12 to 16 weeks (87% of patients had measurable response in 12 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Slow following SubQ injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 78 &plusmn; 32 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Degradation of IgG and omalizumab:IgE complexes by reticuloendothelial system and endothelial cells in the liver</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 62%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 26 days (asthma patients); 24 days (chronic idiopathic urticaria patients)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 7 to 8 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily via hepatic degradation; intact IgG may be secreted in bile</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422269\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Xolair Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (1): $1,276.07</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038711\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ksolar (UA);</li>\n      <li>Xolair (AE, AR, AT, AU, BB, BE, BG, BR, CH, CL, CO, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, ID, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MY, NL, NO, NZ, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, VE, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Berger W, Gupta N, McAlary M, et al, &ldquo;Evaluation of Long-Term Safety of the Anti-IgE Antibody, Omalizumab, in Children with Allergic Asthma,&rdquo; <i>Ann Allergy Asthma Immunol</i>, 2003, 91(2):182-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omalizumab-pediatric-drug-information/abstract-text/12952113/pubmed\" target=\"_blank\" id=\"12952113\">12952113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. <i>N Engl J Med</i>. 2011;364(11):1005-1015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omalizumab-pediatric-drug-information/abstract-text/21410369 /pubmed\" target=\"_blank\" id=\"21410369 \">21410369 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casale TB, Condemi J, LaForce C, et al, &ldquo;Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2001, 286(23):2956-67. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omalizumab-pediatric-drug-information/abstract-text/11743836 /pubmed\" target=\"_blank\" id=\"11743836 \">11743836 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milgrom H, Berger W, Nayak A, et al, &ldquo;Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab),&rdquo; <i>Pediatrics</i>, 2001, 108(2):E36. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omalizumab-pediatric-drug-information/abstract-text/11483846/pubmed\" target=\"_blank\" id=\"11483846\">11483846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milgrom H, Fick RB Jr, Su JQ, et al, &ldquo;Treatment of Allergic Asthma With Monoclonal Anti-IgE Antibody. rhuMAb-E25 Study Group,&rdquo; <i>Engl J Med</i>, 1999, 341(26):1966-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omalizumab-pediatric-drug-information/abstract-text/10607813/pubmed\" target=\"_blank\" id=\"10607813\">10607813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strunk RC and Bloomberg GR, &quot;Omalizumab for Asthma,&quot; <i>N Engl J Med</i>, 2006, 354(25):2689-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omalizumab-pediatric-drug-information/abstract-text/16790701/pubmed\" target=\"_blank\" id=\"16790701\">16790701</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xolair (omalizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc; September 2014. </div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12905 Version 100.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709181\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F203365\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F855143\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060686\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060679\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F203343\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F203329\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874749\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060690\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F203360\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060689\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9525624\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F203387\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F203348\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F203333\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299788\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221997\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F203350\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060685\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F203332\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F203347\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422269\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038711\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12905|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=omalizumab-drug-information\" class=\"drug drug_general\">Omalizumab: Drug information</a></li><li><a href=\"topic.htm?path=omalizumab-patient-drug-information\" class=\"drug drug_patient\">Omalizumab: Patient drug information</a></li></ul></div></div>","javascript":null}